>> HOMEPAGE

Heart Failure

Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure.

Mancini M; Rengo F; Lingetti M; Sorrentino GP; Nolfe G

Arzneimittelforschung 1992 Sep;42(9):1101-4

A double-blind phase II study of propionyl-L-carnitine (CAS 17298-37-2) versus placebo was carried out on a group of 60 patients with mild to moderate (II and III NYHA class) congestive heart failure. The group was made up of men and women aged between 48 and 73 years in chronic treatment with digitalis and diuretics for at least 3 months and who still displayed symptoms. Thirty of these patients were chosen randomly and for 180 days, 500 mg of propionyl-L-carnitine was orally administered, 3 times a day in addition to their usual treatment. At basal conditions and after 30, 90 and 180 days the maximum exercise time was evaluated using an exercise tolerance test performed on an ergometer bicycle and the left ventricular ejection fraction was tested by means of bidimensional echocardiography. After one month of treatment, the patients treated with propionyl-L-carnitine, compared to the control group, showed significant increases in the values of both tests, increases which became even more evident after 90 and 180 days. At the stated times the increases in the maximum exercise time were 16.4%, 22.9%, and 25.9%, respectively. The ventricular ejection fraction increased by 8.4%, 11.6% and 13.6%, respectively. On the basis of these results, having studied the particular mechanism of action of propionyl-L-carnitine the authors conclude that it represents a drug of undoubted therapeutic interest in patients with congestive heart failure, in whom it could be efficaciously administered along with a standard pharmacological therapy.

Sitemap

Was ist neu:

Unsere Verantwortung für die Schaffung einer Welt der Gesundheit, des Friedens und der sozialen Gerechtigkeit

Neue Studie würdigt die Rolle von Vitamin C bei der Reduktion von herzkreislaufbedingter Sterblichkeit

Mehr Kranke bitte! – Abrechnungsbetrügerei mit System

Wenn Arzneimittel verpflichtend werden: Pharma stiftet Gerichte dazu an, Opiod-Abhängige einem Drogenprogramm zu unterwerfen – mit Kosten von $1000 je Injektion

Depressionen infolge Vitamin B-Mangel – ein neuer wissenschaftlicher Review steigert die Beweislast

Neue Metaanalyse stellt wiederum den Nutzen von Magnesium bei Bluthochdruck unter Beweis

Die Cholesterin-Herzinfarkt-Hypothese ist “tot”, bestätigt die britische Königliche Pharmazeutische Gesellschaft

Erfrischung pur – Über die Bedeutung von Trinkwasser im menschlichen Körper

» Natürliche Gesundheit

» "Geschäft m. d. Krankheit"

» Internationale Kampagne

» Dr. Raths Offene Briefe

» Studien weltweit

» Studien auf Deutsch

» Helfen Sie mit!

» Codex Alimentarius

» Dossiers

» Sitemap

Dr. Rath Health Foundation auf Facebook Dr. Rath Health Foundation auf YouTube Dr. Rath Health Foundation auf Twitter RSS
 © 2017 Dr. Rath Health Foundation | Kontakt | Impressum | RSS Feed